Rociletinib: Phase I/II data

Data from 27 evaluable NSCLC patients with the T790M EGFR resistance mutation in a Phase I/II trial showed that twice-daily 500 and 625 mg oral rociletinib led to an ORR of 67%, a disease control rate...